[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arrhythmogenic-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arrhythmogenic-cardiomyopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,70,98,141,188,217,241],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100529472","phase-2-targeted-therapy-with-glycogen-synthase-kinase-3-inhibition-for-arrhythmogenic-cardiomyopathy-100529472",false,"NCT06174220","Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy","TaRGET","Inclusion Criteria:\n\n* A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP\\*) rare variant OR the TMEM43-p.S358L variant\n\n  \\*JUP carriers must be homozygous or compound heterozygous\n* Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor\n* Clinical ACM diagnosis or recognition of genetic carrier status for ≥ 6 months prior to screening\n\nExclusion Criteria:\n\n* NYHA class IV heart failure\n* Ventricular scar secondary to coronary artery disease\n* Initiation, cessation, or dose change of a Class I or III anti-arrhythmic drug in the 3 months prior to screening\n* Any potentially harmful chronic liver disease\n* ALT value \\> 2X the upper limit of the normal reference range at Screening\n* Total bilirubin value greater than the upper limit of the normal reference range at Screening, unless documented Gilbert's syndrome. For individuals with Gilbert's syndrome, total bilirubin value greater than 2-fold the upper limit of the normal reference range at Screening.\n* A history of alcohol or illicit substance use disorders\n* Regular and long-term use of strong CYP3A4 inhibitors, including clarithromycin, telithromycin, ketoconazole, itraconazole, posaconazole, nefazodone, idinavir and ritonavir\n* Serum creatinine \\> 150 micromole\u002FL or creatinine clearance ≤ 60 mL\u002Fmin (according to Cockcroft-Gault formula) at Screening\n* Pregnant at time of enrollment and women of childbearing age who do not use a highly effective form of contraception\n* Males, engaged in sexual relations with a female of child-bearing potential, not using an acceptable contraceptive method if not surgically sterile\n* Patients unwilling to provide informed consent or comply with follow-up\n* Hypersensitivity to tideglusib or any components of its formulation, including allergy to strawberry\n* Concurrent use of drugs metabolized by CYP3A4 with a narrow therapeutic window e.g. warfarin and digoxin","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.",[26,27],"Arrhythmogenic Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy",[29],"sudden cardiac death, ventricular cardiomyopathy, genetics, arrhythmia","RECRUITING","2026-03-10",{"date":33,"type":34},"2026-03-12","ACTUAL",{"date":36,"type":34},"2025-03-21",{"date":38,"type":20},"2027-07-01",{"name":40,"class":41},"Hamilton Health Sciences Corporation","OTHER",17,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100620209","the-application-of-t1-mapping-in-real-world-100620209","NCT07354646","The Application of T1 Mapping in Real-World","The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort","Inclusion Criteria:\n\n1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.\n2. Specific disease categories include:\n\n   * Cardiomyopathies (HCM, DCM, RCM, ACM)\n   * Infiltrative disorders (cardiac amyloidosis, Fabry disease)\n   * Inflammatory conditions (acute\u002Fchronic myocarditis)\n   * Ischemic heart disease (acute\u002Fchronic MI)\n   * Valvular heart disease (aortic stenosis)\n   * Arrhythmic conditions (atrial fibrillation)\n   * Metabolic disorders (iron-overload)\n   * Neoplastic conditions (cardiac tumors)\n   * Congenital heart disease\n   * Post-transplant evaluation\n3. All diagnoses must be confirmed using established guideline-based criteria:\n\n   * Echocardiographic parameters meeting disease-specific cutoffs\n   * Cardiac MRI findings consistent with current consensus criteria\n   * Laboratory biomarkers supporting respective diagnoses\n   * Histopathological confirmation when clinically indicated\n\nExclusion Criteria:\n\n* Presence of multiple cardiomyopathy diseases or risk factors simultaneously\n* Contraindications to CMR examination\n* Poor image quality precluding accurate T1 mapping analysis\n* Incomplete clinical data for definitive diagnosis confirmation\n* Pregnancy or lactation\n* Inability to provide informed consent",true,{"count":52,"type":20},2000,"OBSERVATIONAL","The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:\n\nWhat are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler \"native T1\" measurement (without contrast dye) instead of the more complex \"ECV\" measurement (which requires contrast dye) for diagnosis?\n\nPatients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping",[56,57,58,26,59],"Myocardial Infarction (MI)","Hypertrophic Cardiomyopathy (HCM)","Dilated Cardiomyopathy (DCM)","Myocarditis","2026-01-12",{"date":62,"type":34},"2026-01-21",{"date":64,"type":34},"2020-03-01",{"date":66,"type":20},"2026-12-01",{"name":68,"class":41},"Chinese Academy of Medical Sciences, Fuwai Hospital",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100587023","phase-2-statin-effect-on-arrhythmogenic-cardiomyopathy-disease-progression-search-100587023","NCT06922994","Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)","Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression","SEARCH","Inclusion Criteria:\n\n1. Participant must be at least 18 years of age, at the time of signing the informed consent\n2. Participants affected by Arrhythmogenic Cardiomyopathy as defined by task force criteria\n\nExclusion Criteria:\n\n1. Known hypersensitivity to atorvastatin or any of the excipients\n2. Moderate or severe liver disease\n3. Muscle disease\n4. Left ventricular ejection fraction \\\u003C35%\n5. Congestive heart failure defined by the New York Heart Association (NYHA) as class III or IV.\n6. Known cardiomyopathy of other origin: post ischemic, hypertrophic, idiopathic dilated, restrictive; known moderate-to-severe mitral or aortic valvulopathy; pulmonary hypertension; congenital cardiac abnormalities\n7. Hypercholesterolemic patients that require the use of lipid lowering drugs.\n8. Heart transplantation\n9. Estimated life expectancy of less than 2 years\n10. Any other medical condition that, in the judgment of the investigator, places the patient at risk or makes the patient unreliable or limits the patient's ability to complete the study\n11. Potent CYP3A4 modifiers such as Erythromycin, Clarithromycin Azole antifungals, Protease inhibitors , Gemfibrozil, Ciclosporin, Danazol\n12. Fusidic acid (drug for bacterial infections)\n13. Hepatitis C antivirals as telaprevir, boceprevir, glecaprevir\u002Fpibrentasvir and ledipasvir\u002Fsofosbuvir combination\n14. Any other lipid lowering drugs such as Statins, Cholesterol absorption inhibitors, Bile acid sequestrants , PCSK9 inhibitors, Adenosine triphosphate-citrate lyase inhibitors , Fibrates, Omega-3 fatty acid ethyl esters\n15. Drugs primary indicated as antioxidants\n16. Enrollment in another clinical trial or past clinical trial in which an investigational drug was administered within 30 days of Visit 1 or within the 5 half-lives of the investigational drug, whichever is longer.\n17. Pregnant or lactating women\n18. Women of childbearing age who are not using adequate contraception\n19. Known dependency on alcohol - drug abuse.\n20. Contraindications to cardiac magnetic resonance",{"count":79,"type":20},102,[23],"The goal of this clinical trial is to learn if Atorvastatin 80 mg is effective to avoid functional right ventricular deterioration in patients affected by Arrhythmogenic Cardiomyopathy. It will also learn about the safety of Atorvastatin 80 mg in this type of patients. The main questions it aims to answer are:\n\n1. Does Atorvastatin 80 mg prevent worstening of the right ventricular functioning?\n2. Does Atorvastatin 80 mg prevent the worsening of electric, morphological and biomarkers deterioration?\n3. What medical problems do participants have when taking Atorvastatin 80 mg?\n\nResearchers will compare Atorvastatin 80 mg to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat Arrhythmogenic Cardiomyopathy.\n\nParticipants will:\n\n1. Take Atorvastatin 80 mg or a placebo every day for 18 months;\n2. Visit the clinic at the enrollment and after 2, 4, 9 and 18 months for checkups and tests;\n3. Make a phone call for safety check after 12, 15 and 19 months since the enrollment;\n4. Fill out psychological questionnaires",[26],[84,85,86,87],"Atorvastatin","Strain","Disease progression risk","Arrhythmias","2025-07-02",{"date":90,"type":34},"2025-07-03",{"date":92,"type":34},"2025-03-31",{"date":94,"type":20},"2026-11-30",{"name":96,"class":41},"Centro Cardiologico Monzino",5,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":107,"targetDuration":109,"studyType":53,"phases":4,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":140},"100591144","a-study-to-assess-real-world-patient-characteristics-and-clinical-course-for-symptomatic-patients-with-pkp2-acm-100591144","NCT06976606","A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM","An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy (ACM) Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)","SNAPSHOT- PKP2","Inclusion Criteria:\n\n* Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)\n* Documentation of a pathogenic or likely pathogenic truncating variant in PKP2\n* Frequent premature ventricular contractions (PVCs)\n* Patients must have an ICD placed prior to enrollment\n* Left ventricular ejection fraction (LVEF) ≥ 50% for Part A participants. Left ventricular ejection fraction (LVEF) ≥40% for Part B participants.\n\nExclusion Criteria:\n\n* Evidence of variant(s) in addition to PKP2 that meet standard criteria to be considered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy.\n* A history of other cardiac abnormalities as specified in the protocol.\n* New York Heart Association symptoms of heart failure of Class IV at the time of consent.\n* A history of prior gene transfer therapy.","65 Years",{"count":108,"type":20},40,"1 Year","An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.",[26,112,113],"PKP2-ACM","PKP2-ARVC",[26,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129],"ACM","Cardiomyopathy","ARVC","Arrhythmogenic Right Ventricular","Arrhythmogenic Right Ventricular Dysplasia","Genetic cardiomyopathy","Gene Therapy","PKP2 Gene","Plakophilin-2","LX2020","SNAPSHOT-PKP2","Ventricular Arrhythmia","PVCs","Sudden Cardiac Death","Cardiac Arrest","2025-05-13",{"date":132,"type":34},"2025-05-16",{"date":134,"type":34},"2024-01-23",{"date":136,"type":20},"2027-09",{"name":138,"class":139},"Lexeo Therapeutics","INDUSTRY",6,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":149,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":152,"conditions":153,"keywords":168,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100578603","characterization-of-patients-with-cardiomyopathy-to-identify-critical-patients-candidates-for-cardiac-transplantation-100578603","NCT06813443","Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation","Clinical, Instrumental, and Molecular (Circulating and Tissue microRNAs) Characterization of Patients With Cardiomyopathy to Identify Critical Patients With Severe Organ Failure to be Candidates for Cardiac Transplantation","CMPMIRNA","Inclusion Criteria:\n\n* Patients diagnosed with CMP according to current international guidelines\n* Age ≥ 12 years at the time of diagnosis\n* Obtaining informed consent from the patient and the parent or legal guardian (in the case of patients aged \\\u003C 18 years)\n\nExclusion Criteria:\n\n* none","12 Years",{"count":151,"type":20},700,"The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and spatial transcriptomics, which are emerging techniques that may provide insights into the underlying disease mechanisms. By understanding these markers, the investigators hope to improve the way the investigators diagnose and manage CMP, particularly in terms of predicting progression to heart failure or heart transplantation.\n\nThe study will evaluate patients with hypertrophic cardiomyopathy (e.g., sarcomeric forms, Anderson-Fabry disease, AL, and TTR cardiac amyloidosis), dilated cardiomyopathy and arrhythmogenic cardiomyopathy. These patients will undergo clinical evaluations, including ECG, echocardiograms, CMR, biopsy analysis, and genetic testing, as well as molecular studies such as transcriptomics and miRNA analysis. This comprehensive approach aims to identify potential new biomarkers for diagnosing and predicting the disease course.",[154,155,156,26,57,157,158,159,160,128,161,162,163,164,165,166,167],"Cardiomyopathies","Amyloidosis Cardiac","Fabry Disease","Laminopathies","Dystrophia Myotonica","Mitochondrial Cardiomyopathy","Dilated Cardiomyopathy","Heart Transplantation","Glycogen Storage Disease","Infiltrative Cardiomyopathy","Cardiac Magnetic Resonance Imaging","Electrocardiogram","Micro RNA","Echocardiogram",[169,170,171,172,173,174,175,176,177],"cardiomyopathy","cardiac amyloidosis","Fabry disease","hypertrophic cardiomyopathy","dilated cardiomyopathy","sudden cardiac death","arrhythmogenic cardiomyopathy","heart failure","heart transplantation","2025-02-03",{"date":180,"type":34},"2025-02-07",{"date":182,"type":34},"2023-02-13",{"date":184,"type":20},"2027-12-14",{"name":186,"class":41},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",3,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":196,"targetDuration":198,"studyType":53,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100572222","image-based-prediction-of-ventricular-tachycardia-events-in-non-ischemic-cardiomyopathy-100572222","NCT06730464","Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy","Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy, an International Multicenter Study - [The IMPROVE-NICM Study]","IMPROVE-NICM","Inclusion Criteria:\n\n* Diagnosis of non-ischemic heart disease involving the left ventricle, irrespectively of LVEF. This diagnosis includes:\n\n  1. Dilated cardiomyopathy (DCM)\n  2. Non-dilated left ventricular cardiomyopathy (NDLVC)\n  3. Post-myocarditis cardiomyopathy\n* Life expectancy of \\> 1 year with a good functional status.\n* Signed informed consent.\n* At least one late gadolinium enhancement-cardiac magnetic resonance (LGE-CMR) already performed.\n* No VA events at the time of the 1st LGE-CMR study.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Life expectancy of \\\u003C 1 year, or bad functional status (NYHA IV functional class).\n* Other concomitant structural heart diseases (e.g. ischemic, congenital, arrhythmogenic right ventricular cardiomyopathy etc.)\n* No LGE-CMR at time of enrollment or LGE-CMR data not available.\n* Previously documented sustained ventricular arrhythmias at the time of 1st LGE-CMR.\n* Concomitant investigation treatments.\n* Medical, geographical and social factors that make study participation impractical, and inability to give written informed consent. Patient's refusal to participate in the study.",{"count":197,"type":20},500,"2 Years","Risk stratification for sudden cardiac death (SCD) in patients with non-ischemic cardiomyopathy (NICM) remains suboptimal. Although current guidelines rely on severe left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) \\\u003C 35%) as key predictor of arrhythmic risk and clinical indication of prophylactic implantable cardioverter defibrillator (ICD), this approach seems inadequate, since registries report that only a minority of NICM ICD carriers experience an appropriate ICD shock during follow-up, whereas out-of-hospital cardiac arrests (OHCA) occur in patients with LVEF\\>35% in up to 80% of cases. Moreover, pivotal primary prevention trials (DANISH trial, long-term outcome of the SCD-HeFT trial) failed to demonstrate a net mortality benefit of ICD in patients with NICM.\n\nAs for most structural heart diseases (SHD), scar-related reentry has been addressed as the pathophysiological mechanism of ventricular arrhythmias (VAs) in patients with NICM, with fibrotic tissue being the substrate of this reentry. Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) is the gold standard for the non-invasive visualization and characterization of the myocardial fibrosis and according to retrospective studies is detected in nearly 30% of patients with NICM.\n\nIn latest years, several studies and subsequent metanalyses have explored the correlation between CMR-detected LGE and occurrence of VAs, showing that presence, extent, location (septal vs lateral) and patten (focal vs multifocal vs ring-like) of non-ischemic fibrosis help in stratifying arrhythmic risk.\n\nNonetheless, scar heterogeneity (that is, inherent composition of dense scars vs border zone (BZ), presence of strands of viable myocardium within the scar) has been indicated as a potential novel predictor of VAs. In a recent prospective multicenter registry on patients with class I indication for cardiac resynchronization therapy (CRT) (\\>60% with NICM), not only scar mass, but even border zone (BZ) mass and presence of BZ channels were identified as independent predictors for VT occurrence in NICM patients.\n\nThis BZ mass and BZ channels can be automatically identified using a commercially available, post-processing imaging platform named ADAS 3D LV (ADAS3D Medical SL, Barcelona, Spain), with FDA 510(k) Clearance and CE Mark approval. Thus, CMR-derived BZ mass might be used as an automatically reproducible criterium to reclassify those patients with NICM at highest risk for developing VAs\u002FSCD in a relatively short period of at least 2 years.\n\nIn the present cohort study, the investigators sought to: i) evaluate the usefulness of CMR-derived BZ mass measurement and identification of heterogeneous tissue channels (HTC) (among other scar characteristics derived from image post-processing) to predict the occurrence of VT events in an international, retrospective, multicenter, unselected series of patients with NICM without previous arrhythmia evidence (main study); ii) subsequently validate these predictors of VT occurrence in a prospectively-collected multicenter cohort study (substudy 1); iii) retrospectively evaluate in the subset of patients with \\> 1 LGE-CMR performed as part of standard clinical practice if any change in BZ mass and HTC presence occurs over time and if this correlates with occurrence of VAs (substudy 2).",[160,26,126,201],"Hypertrophic Cardiomyopathies",[203,204,205,206],"Dilated cardiomyopathy","Non-dilated left ventricular cardiomyopathy (NDLVC)","border zone channels","ventricular arrhythmias","2024-12-08",{"date":209,"type":34},"2024-12-12",{"date":211,"type":34},"2024-10-07",{"date":213,"type":20},"2027-02-23",{"name":215,"class":41},"Centro Medico Teknon",4,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":69},"100543164","risk-stratification-early-prevention-and-treatment-strategies-for-arrhythmogenic-cardiomyopathy-100543164","NCT06352307","Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy","Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy (STARTER): a Multicenter Retro-prospective Cohort Study","STARTER","Inclusion Criteria:\n\n* Age \\>18 years old.\n* The diagnosis of ACM was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing.\n* Patients or their families agreed to participate in the study and authorized informed consent.\n\nExclusion Criteria:\n\n* Incomplete clinical data.\n* Do not agree to the inclusion or refuse to authorize the informed consent.",{"count":226,"type":20},1500,"This study will include patients diagnosed with Arrhythmogenic cardiomyopathy (ACM) in the First Affiliated Hospital of Xi 'an Jiaotong University and other centers, and collect clinical data and biological samples of patients with different ACM phenotypes. Through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of ACM.",[26],[230,231],"Arrhythmogenic cardiomyopathy","Prognostic factors","2024-07-10",{"date":234,"type":34},"2024-07-12",{"date":236,"type":34},"2024-04-09",{"date":238,"type":20},"2032-08-31",{"name":240,"class":41},"First Affiliated Hospital Xi'an Jiaotong University",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":257,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":69},"100483001","diagnostic-contribution-prognosis-and-physiopathological-aspects-in-arrhythmogenic-cardiomyopathy-acore-100483001","NCT05569356","Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy. (ACORE)","Biomarkers of Inflammation and Autoimmunity: Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy.","ACORE","Inclusion Criteria:\n\n1. Adult patient (age ≥ 18 years old)\n2. Patient with a probable or confirmed diagnosis of cardiomyopathy according to the diagnostic criteria of the international task force\n3. Patient carrying a pathogenic mutation responsible for cardiomyopathy\n4. Patient informed individually of the research\n\nExclusion Criteria:\n\n1. Patients under curatorship\u002Fguardianship\n2. Pregnant women\n3. Patients who expressed their opposition to participate in the study","100 Years",{"count":251,"type":20},300,"This study aims to identify novel inflammatory biomarkers in AC, whether in circulating blood, in situ or as imaging biomarkers to better understand the pathophysiology of the disease and then to determine contribution to the clinical management of patients.",[26],[26,255,256],"Inflammatory biomarkers","Autoantibodies","NOT_YET_RECRUITING","2022-10-11",{"date":260,"type":34},"2022-10-13",{"date":262,"type":20},"2022-10-20",{"date":264,"type":20},"2032-10-20",{"name":266,"class":41},"Assistance Publique - Hôpitaux de Paris"]